Oral human gammaglobulin

Drug Profile

Oral human gammaglobulin

Alternative Names: IgPO; Oralgam

Latest Information Update: 09 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sepulveda Ambulatory Care Center; University of California at Los Angeles
  • Developer Protein Therapeutics; Research Corporation Technologies; University of California at Los Angeles
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dermatomyositis; Enterocolitis; Juvenile rheumatoid arthritis
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Crohn's disease; Enterocolitis; Juvenile rheumatoid arthritis; Rheumatoid arthritis

Most Recent Events

  • 29 Apr 2008 Oral gammaglobulin (Oralgam™) licensed to Latona Life Sciences worldwide for the treatment of Juvenile and adult rheumatoid arthritis and auto-immune induced hearing loss
  • 24 Feb 2006 Phase-II clinical trials in Enterocolitis in USA (PO)
  • 24 Feb 2006 PediaMed has completed enrolment in a phase II trial for Autistic enterocolitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top